Key Clinical Takeaway GLP-1 therapy does not mandate blanket micronutrient panels
Would the program end up saving more than $4,000 on other expenses to offset that cost
The combination of peroxidases or systems with peroxidase-like activity with nanostructures such as nanoparticles, nanotubes, thin films, liposomes, micelles, nanoflowers, nanorods and others is often an efficient strategy to improve catalytic activity, targeting, and reusability

Heres a simple breakdown Ozempic (Semaglutide) Class: GLP-1 receptor agonist Helps: Control blood sugar + reduce CV risk Weight loss: Significant (~15%) Once weekly injection Common effects: Nausea, vomiting, diarrhea Extra: Proven cardiovascular benefit in T2D Trulicity (Dulaglutide) Class: GLP-1 receptor agonist Helps: Blood sugar control + CV protection Approved for children 10+ with T2D Weight loss: Modest Once weekly prefilled pen Common effects: GI discomfort Mounjaro (Tirzepatide) Class: Dual GIP + GLP-1 receptor agonist Helps: Powerful glucose control Weight loss: Highest among the three Once weekly (dose escalation) Common effects: GI symptoms (especially during dose increase) All carry a warning for possible thyroid C-cell tumor risk (avoid in patients with MEN2 or medullary thyroid carcinoma history)
The third receptor that interacts with retatrutide, glucagon, targets liver fat and may prompt the body to burn more calories
And after 5 weeks of use, the results are truly amazing